1Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELATE Ⅱ . Lancet, 2000, 355 : 1582-1587.
2Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001,345:1667-1675.
3Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricalar systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003,362:772-776.
4Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of a trial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J, 2006,152 : 86-92.
5Diekstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin Ⅱ Antagonist Eosartan. Lancet, 2002,360:752-760.
6Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med,2003,349:1893-1906.
7Wachtell K, Lehto M, Olsen MH, et al. Angiotensin Ⅱ receptor blockade reduces new-onset a trial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coil Cardiol, 2005,45:712-719.
8Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet,2004,363:2022-2031.
9Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study) : a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet, 2007,369 : 1431-1439.
10Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin Ⅱ receptor antagonist with selective PPAR( gam2ma)2 modulating activitv. Hwertension, 2004,43:993-1002.
3Hernandez Hernandez R,Sosa Canache B,Velasco M,et al.Angiotensin Ⅱ receptor antagonists role in arterial hypertension[J].J Hum Hypertens,2002,16 (Suppl 1):s93.
4Gleiter CH,Morike KE.Clinical pharmacokinetics of candesartan[J].Clin Pharmacokinet,2002,41 (1):7.
5Daholof B,Devercux RB,Kjddsen SE,et al.Cadiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomized trial against atenold[J].Lanect,2002,359:995.
6Ross A,Papademetriou.Candesartan cilexetil in cardiovascular disease[J].Expert Rev Cardiovasc Ther,2004,2 (6):829-835.
8Ostergren J.Candesartan for the treatment of hypertension and heart failure[J].Expert Opin Pharmacother,2004,5 (7):1589-1597.
9Zanchetti A,Omboni S.Comparision of candesartan versus enalapril in essential hypertension.Italian Candesartan Study Group[J].Am J Hypertens,2001,14:129-134.
10Kloner RA,Weinberger M,Pool JL,et al.Comparative effects of candesartan cilexetil and amLodipine in patients with mild systemic hypertension.Comparison of Candesartan and Amlodipine for Safety,Tolerability and Efficacy (CASTLE)study investigators[J].Am J Cardiol,2001,15,87:727-731.
5Maczewski M,Borys M,Kacprzak P,et al.Angiotensin II AT1 receptor density on blood platelets predicts early left ventricular remodelling in non-reperfused acute myocardial infarction in humans.Eur J Heart Fail,2006,8:173-178.
6Doering CW,Jalil JE,Janicki JS,et al.Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy.Cardiovasc Res,1988,22:686-695.
7Raizada V,Skipper B,Luo W,et al.Intracardiac and intrarenal renin-angiotensin systems:mechanisms of cardiovascular and renal effects.J Invest Med,2007,55:341-359.
8Billet S,Aguilar F,Baudry C,et al.Role of angiotensin II AT1 receptor activation in cardiovascular diseases.Kidney Int,2008,74:1379-1384.
9Lapointe N,Rouleau JL.Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure-effects of ACE inhibitors.JACC,2002,39:776-778.
10Bahk TJ,Daniels MD,Leon JS,et al.Comparison of angiotensin converting enzyme inhibition and angiotensin Ⅱ receptor blockade for the prevention of experimental autoimmune myocarditis.Int J Cardiol,2008,125:85-93.
